Biotech Analysis Central Pharma News: Galectin's Failure, Revance's...

Biotech Analysis Central Pharma News: Galectin's Failure, Revance's...


Novo Nordisk obtains FDA approval for its type II diabetes drug Ozempic, looks to take on Eli Lilly's Trulicity. Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.



from Biotech News